Preparation of no-carrier-added 161Tb by lanthanide resin
10.3760/cma.j.cn321828-20220217-00049
- VernacularTitle:利用镧系树脂制备无载体 161Tb
- Author:
Peng ZHAO
1
;
Liangang ZHUO
;
Xiaoyu GUO
;
Yufeng DANG
;
Gang LI
;
Jing WANG
;
Xia YANG
;
Wei LIAO
;
Hongbo LI
;
Xiaoling XIONG
;
Qingchuan LIN
;
Hongyuan WEI
;
Jun TU
;
Yuchuan YANG
Author Information
1. 中国工程物理研究院核物理与化学研究所，绵阳 621999
- Keywords:
Lanthanoid series elements;
Resins, synthetic;
Terbium;
Gadolinium
- From:
Chinese Journal of Nuclear Medicine and Molecular Imaging
2022;42(6):325-329
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To produce 161Tb from enriched 160Gd 2O 3 isotope-enriched target material and realize domestic production of the novel medical isotope 161Tb. Methods:The 160Gd 2O 3 isotope-enriched target material was irradiated with neutrons by the China Mianyang Research Reactor (CMRR). The no-carrier-added 161Tb product was obtained after the processes of target broken, sample dissolution, separation and purification with lanthanide (LN) resin and solution replacement with diglycolamide (DGA) column. Various key indicators such as γ spectral purity, metal impurity content, specific activity, radiochemical purity, and radioactive concentration were used to conduct the quality inspection and the control of 161Tb products. Results:161TbCl 3 of 33.4 GBq was obtained in a single time with the radioactive concentration of 16.8 GBq/ml, nuclear purity more than 99.9%, and radiochemical purity of 99.2%. Metal impurity content was met the established standards, with the specific activity of 6.02×10 17 Bq/mol. The radiochemical purities of 161Tb labeling with 1, 4, 7, 10-tetraazacyclododecane-1, 4, 7, 10-tetraacetic acid- D-Phe1-Tyr3-Thr8-octreotide (DOTATATE) after 0 and 72 h were 100% and 95.8% respectively. Conclusion:The preparation of no-carrier-added 161Tb by using LN resin has the advantages of high separation performance and high sample loading, which has great significance in the field of medical isotope preparation and lays a good nuclide guarantee for the research and development of domestic 161Tb-labeled drugs.
